Evidence map›Paper›PMID 40363718›Full record

ReviewMolecules (Basel, Switzerland)2025

Hepatoprotective Effect of Kaempferol-A Review.

Przemysław Niziński, Anna Krajewska, Tomasz Oniszczuk, Beata Polak, Anna Oniszczuk

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Exploring the Nutraceutical Potential ofFood science & nutrition · 2026
    Review
  6. Review
  7. Review
  8. Article
  9. Kaempferol inhibits hepatitis B virus replicationFrontiers in cellular and infection microbiology · 2026
    Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Przemysław NizińskiDepartment of Pharmacology, Medical University of Lublin, Radziwiłłowska 11, 20-080 Lublin, Poland.ORCID 0000-0003-1724-0089
Anna KrajewskaDepartment of Comprehensive Paediatric and Adult Dentistry, Medical University of Lublin, Chodżki 6, 20-093 Lublin, Poland.
Tomasz OniszczukDepartment of Thermal Technology and Food Process Engineering, University of Life Sciences in Lublin, Głęboka 31, 20-612 Lublin, Poland.ORCID 0000-0002-1061-6541
Beata PolakDepartment of Physical Chemistry, Medical University of Lublin, Chodżki 4a, 20-093 Lublin, Poland.
Anna OniszczukDepartment of Inorganic Chemistry, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland.ORCID 0000-0002-5109-3302

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver diseases, including chronic inflammation and related metabolic dysfunction-associated steatotic liver disease (MASLD), fibrosis and cirrhosis remain a growing global health burden. Currently, available pharmacotherapy for liver dysfunction has limited efficacy. Kaempferol, a naturally occurring flavonoid, has demonstrated significant hepatoprotective effects in preclinical models. This substance activates the SIRT1/AMPK signalling pathway, improves mitochondrial function, inhibits proinflammatory cytokine production via TLR4/NF-κB suppression and attenuates hepatic stellate cell activation by modulating the TGF-β/Smad pathway. In addition, kaempferol regulates the composition of the gut microbiota, thus improving bile acid metabolism and alleviating steatosis and fibrosis. This review presents an integrated analysis of recent in vitro and in vivo studies on the mode of action and utility of kaempferol in liver disease and hepatoprotection.

Indexed as

KaempferolsLiverLiver DiseasesProtective AgentsAnimalsGastrointestinal MicrobiomeHepatic Stellate CellsHumansSignal TransductionkaempferolKaempferolsProtective AgentsantioxidantsfibrosisflavonoidskaempferolliverLPSMASLD

Identifiers

PMID40363718
PMCPMC12073652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.